Trial · NCT02242695
Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis
NCT02242695, Phase 4, Completed, Medinova AG
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis. Trials, record NCT02242695. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02242695
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis
- NCT number
- NCT02242695
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 150 participants, actual
- Lead sponsor
- Medinova AG
- Conditions
- Vulvovaginal Candidiasis
- Interventions
- Fluomizin vaginal tablets, Canesten vaginal tablets
- First posted
- 2014-09-17
- Last updated
- 2016-09-15
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure rate | Control 1 at day 4 after therapy end | Clinical cure rate is defined as Total Severity Score (TSC) ≤ 2 |
| Secondary | Microbiological cure rate | Control 1 at 4 days after therapy end | Negative microscopy for showing yeast forms (hyphae/pseudohyphae) or budding yeasts and Negative Candida culture |
| Secondary | Therapeutic cure rate | Control 1 at 4 days after therapy end | Clinically and microbiologically cured |
| Secondary | Individual clinical signs and symptoms | Control 1 at 4 days after therapy end | 4-point rating scale for vaginal itching, vaginal burning or soreness, vulvo/vaginal erythema or edema, and vulvar excoriation ofr fissure formation |
| Secondary | Presence of dyspareunia | Control 1 at 4 days after therapy end | yes/no |
| Secondary | Direct microscopy (wet smear) | Control 1 at 4 days after therapy end | Presence or absence of Candida hyphea or spores |
| Secondary | vaginal pH | Control 1 at 4 days after therapy end | |
| Secondary | Candida culture | Control 1 at 4 days after therapy end | positive / negative for Candida spp |
| Secondary | Global assessment of efficacy | Control 1 at 4 days after therapy end | 4-point rating scale assessed by investigator and patient |
| Secondary | Patient Satisfaction | Control 1 at 4 days after therapy end | presence of vaginal discomfort, increased discharge, burning sensation |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32940765 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02242695
GET https://conductscience.org/api/trials/v1/NCT02242695/registered?page=2